Patients & Caregivers
Gastrointestinal Stromal Tumors
Treatment
Surgery is the standard treatment for primary resectable GIST. However, surgical resection is seldom curative, and by five years after complete removal of their tumor, half of patients having undergone such cancer treatments treated have relapsed.
Imatinib is the first-line treatment in patients with metastatic or unresectable GIST. It has resulted in durable objective response or stable disease in approximately 85% of patients with advanced GIST and is well tolerated.
‹ previous section | next section ›
SEARCH OUR WEBSITES
PRODUCTS
At Novartis Oncology, we strive to provide a broad range of innovative, practical solutions and authoritative resource therapies.
PATIENT STORIES
"My sister died of breast cancer years ago. I'm a cancer survivor-because the battle is a lot different today."
- Carol Lundin
RESEARCH INNOVATION
Novartis maintains the most promising oncology drug pipeline in the industry to treat and help people around the world.